Public Health England found that two doses of the Pfizer and AstraZeneca vaccine could still keep patients with the Delta variant out of hospital - but both are now less able to stop infection in the first place.
Here, we interview Alex Wilson, Co-founder of specialist reagent company PCR Biosystems, discussing how their expertise in enzyme development and large-scale production has been successfully applied to COVID-19 testing solutions around the world.
Today (14 June) the Commission formally signed legislation to create the EU Digital COVID Certificate - which will be used for 12 months, beginning from 1 July, 2021.
A new study found that the Novavax vaccine was 93.2% effective against the Alpha variant - with no clarification about vaccine performance against the Delta variant.
Imogen Keane, Business Development Manager at Service Robotics Ltd, explores how the remote care revolution is helping to address loneliness for the most vulnerable in our communities.
Postpartum mental health visits for new mothers increased by 30% during the COVID-19 pandemic, as researchers suggest that the increased use of virtual appointments may have removed barriers to care.
Digitalisation continues to grow in many sectors, resulting in significant demand for skills-based education and training - Here, Professor Neil Morris argues for growth of online education.
Scientists analysed 59,000 Icelandic adolescents to understand the psychological impact of COVID-19 - now, they say the pandemic has significantly harmed the mental health of teenage girls.
According to research by Cambridge University, urban crime levels dropped roughly 37% over COVID lockdowns - across 23 different countries in Europe, the Americas, Asia and the Middle East.
The UK's Alpha variant became one of the most highly transmitted forms of the virus, which led to other variants mutating into existence - now, scientists are picking up on the beginnings of a "Mexican variant", yet to be named under the WHO system.
A team at Newcastle University have identified a gene, HLA-DRB1*04:01, which could be responsible for individuals who are asymptomatic - suggesting that the gene offers some protection against severe COVID.
Scientists have found that neurological symptoms, like fatigue, are more common in people with mild COVID cases - as opposed to only in severe COVID cases.
